Probiotics synergized with conventional regimen in managing Parkinson’s disease

Sun, Hairong; Zhao, Feiyan; Liu, Yuanyuan; Ma, Teng; Jin, Hao; Quan, Keyu; Li, Bing; Zhao, Jianhua; Yuan, Xiaoling; Li, Zhenguang; Li, Fang; Kwok, Lai‐Yu; Zhang, Shukun; Sun, Zhihong; Zhang, Jinbiao; Zhang, Heping

doi:10.1038/s41531-022-00327-6

Cited by 72 publications

(76 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sampson et al found that the motor impairment of germ-free PD-like mice worsened when they were administered the gut microbiota of patients with PD, demonstrating the role of gut microbes and short chain fatty acids (SCFAs) in α-synuclein-induced neurotoxicity and inflammation [ 10 ]. By transplanting the microbiota of young healthy mice into older PD mice, Marcus et al showed that the age-related cognitive and behavioral impairments could be corrected, in part through altering the synthesis of SCFA and neurotransmitters [ 11 ]. The results of these studies indicate that one of the major contributors to PD is an imbalance of the gut microbiota.…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Chu

et al. 2022

Nutrients

View full text Add to dashboard Cite

There is mounting evidence that the microbiota–gut–brain axis (MGBA) is critical in the pathogenesis and progression of Parkinson’s disease (PD), suggesting that probiotic therapy restoring gut microecology may slow down disease progression. In this study, we examined the disease-alleviating effects of Bifidobacterium breve CCFM1067, orally administered for 5 weeks in a PD mouse model. Our study shows that supplementation with the probiotic B. breve CCFM1067 protected dopaminergic neurons and suppressed glial cell hyperactivation and neuroinflammation in PD mice. In addition, the antioxidant capacity of the central nervous system was enhanced and oxidative stress was alleviated. Moreover, B. breve CCFM1067 protected the blood–brain and intestinal barriers from damage in the MPTP-induced mouse model. The results of fecal microbiota analysis showed that B. breve CCFM1067 intervention could act on the MPTP-induced microecological imbalance in the intestinal microbiota, suppressing the number of pathogenic bacteria (Escherichia-Shigella) while increasing the number of beneficial bacteria (Bifidobacterium and Akkermansia) in PD mice. In addition, the increase in short chain fatty acids (acetic and butyric acids) may explain the anti-inflammatory action of B. breve CCFM1067 in the gut or brain of the MPTP-induced PD mouse model. In conclusion, we demonstrated that the probiotic B. breve CCFM1067, which can prevent or treat PD by modulating the gut–brain axis, can be utilized as a possible new oral supplement for PD therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Chu

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Limited in vitro experiments have been carried out to evaluate the possible beneficial and neuroprotective effects of probiotics in alleviating the typical features of PD ( Table 1 ) [ 325 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 ].…”

Section: Parkinson’s Disease and Gut Microbiota: Therapeutic Approachesmentioning

confidence: 99%

“…Finally, another randomized, double-blind, placebo-controlled clinical trial, performed by using the probiotic strain Probio-M8 ( B. animalis subsp. lactis Probio M-8), together with conventional drugs (benserazide and dopamine agonists), showed amelioration in sleep quality, cognitive dysfunction, defecation, and attenuation of GI symptoms [ 342 ].…”

Section: Parkinson’s Disease and Gut Microbiota: Therapeutic Approachesmentioning

confidence: 99%

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

Varesi¹,

Campagnoli²,

Fahmideh³

et al. 2022

IJMS

View full text Add to dashboard Cite

The bidirectional interaction between the gut microbiota (GM) and the Central Nervous System, the so-called gut microbiota brain axis (GMBA), deeply affects brain function and has an important impact on the development of neurodegenerative diseases. In Parkinson’s disease (PD), gastrointestinal symptoms often precede the onset of motor and non-motor manifestations, and alterations in the GM composition accompany disease pathogenesis. Several studies have been conducted to unravel the role of dysbiosis and intestinal permeability in PD onset and progression, but the therapeutic and diagnostic applications of GM modifying approaches remain to be fully elucidated. After a brief introduction on the involvement of GMBA in the disease, we present evidence for GM alterations and leaky gut in PD patients. According to these data, we then review the potential of GM-based signatures to serve as disease biomarkers and we highlight the emerging role of probiotics, prebiotics, antibiotics, dietary interventions, and fecal microbiota transplantation as supportive therapeutic approaches in PD. Finally, we analyze the mutual influence between commonly prescribed PD medications and gut-microbiota, and we offer insights on the involvement also of nasal and oral microbiota in PD pathology, thus providing a comprehensive and up-to-date overview on the role of microbial features in disease diagnosis and treatment.

show abstract

“…Promising evidence includes probiotic mediated increases in dopamine [ 16 ], as well as its metabolites, including 3,4-Dihydroxyphenylacetic acid (DOPAC) and Homovanillic acid (HVA) [ 17 ]. Further, probiotics are shown to increase other aspects of neurodegenerative disease, such as improvements in sleep quality, alleviation of anxiety, gastrointestinal symptoms, reduction of oxidative stress and anti-inflammatory effects [ 18 , 19 ]. However, other therapeutic modalities have also been implicated in this regard, although not currently as utilized in practice when compared to probiotics in the context of restoring dopaminergic deficits in neurodegenerative disorders.…”

Section: Introductionmentioning

confidence: 99%

Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson’s Disease and Obesity

Hamamah

Hajnal

Covașă

2022

IJMS

View full text Add to dashboard Cite

Parkinson’s disease (PD), the second most common neurodegenerative disorder worldwide, is characterized by dopaminergic neuron degeneration and α-synuclein aggregation in the substantia nigra pars compacta of the midbrain. Emerging evidence has shown that dietary intake affects the microbial composition in the gut, which in turn contributes to, or protects against, the degeneration of dopaminergic neurons in affected regions of the brain. More specifically, the Mediterranean diet and Western diet, composed of varying amounts of proteins, carbohydrates, and fats, exert contrasting effects on PD pathophysiology via alterations in the gut microbiota and dopamine levels. Interestingly, the negative changes in the gut microbiota of patients with PD parallel changes that are seen in individuals that consume a Western diet, and are opposite to those that adhere to a Mediterranean diet. In this review, we first examine the role of prominent food groups on dopamine bioavailability, how they modulate the composition and function of the gut microbiota and the subsequent effects on PD and obesity pathophysiology. We then highlight evidence on how microbiota transplant and weight loss surgery can be used as therapeutic tools to restore dopaminergic deficits through optimizing gut microbial composition. In the process, we revisit dietary metabolites and their role in therapeutic approaches involving dopaminergic pathways. Overall, understanding the role of nutrition on dopamine bioavailability and gut microbiota in dopamine-related pathologies such as PD will help develop more precise therapeutic targets to rescue dopaminergic deficits in neurologic and metabolic disorders.

show abstract

Probiotics synergized with conventional regimen in managing Parkinson’s disease

Cited by 72 publications

References 89 publications

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson’s Disease and Obesity

Contact Info

Product

Resources

About